290 related articles for article (PubMed ID: 9023557)
1. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
[TBL] [Abstract][Full Text] [Related]
2. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
5. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
[TBL] [Abstract][Full Text] [Related]
6. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
Ordóñez NG
Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
[TBL] [Abstract][Full Text] [Related]
7. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
8. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236
[TBL] [Abstract][Full Text] [Related]
9. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
Brown RW; Clark GM; Tandon AK; Allred DC
Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
[TBL] [Abstract][Full Text] [Related]
10. Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.
Gümürdülü D; Zeren EH; Cagle PT; Kayasel uk F; Alparslan N; Kocabas A; Tuncer I
Pathol Oncol Res; 2002; 8(3):188-93. PubMed ID: 12515999
[TBL] [Abstract][Full Text] [Related]
11. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
12. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L
Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
Roberts F; Harper CM; Downie I; Burnett RA
Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
[TBL] [Abstract][Full Text] [Related]
14. Value of Glut-1 and Koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
Üçer Ö; Dağli AF; Kiliçarslan A; Artaş G
Turk Patoloji Derg; 2013; 29(2):94-100. PubMed ID: 23661345
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemistry in the differential diagnosis of mesothelioma and adenocarcinoma. Evaluation of 5 new antibodies and 6 traditional antibodies].
Chenard-Neu MP; Kabou A; Mechine A; Brolly F; Orion B; Bellocq JP
Ann Pathol; 1998 Dec; 18(6):460-5. PubMed ID: 10051912
[TBL] [Abstract][Full Text] [Related]
16. Distinctive microvillous brush border staining with HBME-1 distinguishes pleural mesotheliomas from pulmonary adenocarcinomas.
Dahlstrom JE; Maxwell LE; Brodie N; Zardawi IM; Jain S
Pathology; 2001 Aug; 33(3):287-91. PubMed ID: 11523926
[TBL] [Abstract][Full Text] [Related]
17. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A
Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062
[TBL] [Abstract][Full Text] [Related]
18. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.
Dejmek A; Hjerpe A
Diagn Cytopathol; 2005 Mar; 32(3):160-6. PubMed ID: 15690331
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data.
King JE; Thatcher N; Pickering CA; Hasleton PS
Histopathology; 2006 Feb; 48(3):223-32. PubMed ID: 16430468
[TBL] [Abstract][Full Text] [Related]
20. Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma.
Attanoos RL; Goddard H; Gibbs AR
Histopathology; 1996 Sep; 29(3):209-15. PubMed ID: 8884348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
